PL377620A1 - Diazynopirymidyny - Google Patents

Diazynopirymidyny

Info

Publication number: PL377620A1
Authority: PL; Poland
Prior art keywords: sup; alkyl; hydrogen; cycloalkyl; haloalkyl
Prior art date: 2002-11-18

Application number

PL377620A

Other languages

English (en)

Inventor

Jian Jeffrey Chen

Kin-Chun Luk

Original Assignee

F. Hoffmann-La Roche Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-18

Filing date

2003-11-12

Publication date

2006-02-06

2003-11-12 Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag

2006-02-06 Publication of PL377620A1 publication Critical patent/PL377620A1/pl

Links

125000000217 alkyl group Chemical group 0.000 abstract 7
229910052739 hydrogen Inorganic materials 0.000 abstract 6
239000001257 hydrogen Substances 0.000 abstract 6
125000000753 cycloalkyl group Chemical group 0.000 abstract 5
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
125000003118 aryl group Chemical group 0.000 abstract 3
125000001188 haloalkyl group Chemical group 0.000 abstract 3
150000002431 hydrogen Chemical class 0.000 abstract 3
125000003545 alkoxy group Chemical group 0.000 abstract 2
125000003710 aryl alkyl group Chemical group 0.000 abstract 2
125000004966 cyanoalkyl group Chemical group 0.000 abstract 2
125000001316 cycloalkyl alkyl group Chemical group 0.000 abstract 2
125000004663 dialkyl amino group Chemical group 0.000 abstract 2
125000004404 heteroalkyl group Chemical group 0.000 abstract 2
125000000623 heterocyclic group Chemical group 0.000 abstract 2
125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 2
239000012826 P38 inhibitor Substances 0.000 abstract 1
125000002252 acyl group Chemical group 0.000 abstract 1
125000002947 alkylene group Chemical group 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004475 heteroaralkyl group Chemical group 0.000 abstract 1
125000001072 heteroaryl group Chemical group 0.000 abstract 1
125000004415 heterocyclylalkyl group Chemical group 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Ophthalmology & Optometry (AREA)
Immunology (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Endocrinology (AREA)
Cardiology (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Transplantation (AREA)
Psychiatry (AREA)
Urology & Nephrology (AREA)
Reproductive Health (AREA)
Molecular Biology (AREA)
Vascular Medicine (AREA)

PL377620A 2002-11-18 2003-11-12 Diazynopirymidyny PL377620A1 (pl)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US42765202P	2002-11-18	2002-11-18

Publications (1)

Publication Number	Publication Date
PL377620A1 true PL377620A1 (pl)	2006-02-06

Family

ID=32326577

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PL377620A PL377620A1 (pl)	2002-11-18	2003-11-12	Diazynopirymidyny

Country Status (14)

Country	Link
US (2)	US6943158B2 (pl)
EP (1)	EP1565475B1 (pl)
JP (1)	JP2006514624A (pl)
KR (1)	KR20050075028A (pl)
CN (1)	CN100357293C (pl)
AT (1)	ATE427951T1 (pl)
AU (1)	AU2003283393A1 (pl)
BR (1)	BR0316375A (pl)
CA (1)	CA2506565A1 (pl)
DE (1)	DE60327097D1 (pl)
MX (1)	MXPA05005028A (pl)
PL (1)	PL377620A1 (pl)
RU (1)	RU2340618C2 (pl)
WO (1)	WO2004046152A1 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2584485C (en) *	2004-10-20	2013-12-31	Resverlogix Corp.	Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases
JP5368792B2 (ja) *	2005-07-29	2013-12-18	レスバーロジックスコーポレイション	複合疾患の予防および処置のための薬学的組成物および挿入可能な医療用デバイスによるその送達
US20090192164A1 (en) *	2006-06-28	2009-07-30	Aska Pharmaceutical Co., Ltd.	Treating agent of inflammatory bowel disease
EP1918284A1 (en) *	2006-10-30	2008-05-07	Glaxo Group	Hydrazinopyrimidines as cysteine protease inhibitors
DK2118074T3 (en) *	2007-02-01	2014-03-10	Resverlogix Corp	Compounds for the prevention and treatment of cardiovascular diseases
KR101629356B1 (ko)	2008-06-26	2016-06-13	리스버로직스 코퍼레이션	퀴나졸리논 유도체의 제조방법
DE102008063561A1 (de) *	2008-12-18	2010-08-19	Bayer Cropscience Ag	Hydrazide, Verfahren zu deren Herstellung und deren Verwendung als Herbizide und Insektizide
NZ594332A (en)	2009-01-08	2013-09-27	Resverlogix Corp	Compounds for the prevention and treatment of cardiovascular disease
WO2010099139A2 (en)	2009-02-25	2010-09-02	Osi Pharmaceuticals, Inc.	Combination anti-cancer therapy
US8465912B2 (en)	2009-02-27	2013-06-18	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
WO2010099138A2 (en)	2009-02-27	2010-09-02	Osi Pharmaceuticals, Inc.	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8642834B2 (en)	2009-02-27	2014-02-04	OSI Pharmaceuticals, LLC	Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
KR101709492B1 (ko)	2009-03-18	2017-02-23	리스버로직스 코퍼레이션	신규한 소염제
US9757368B2 (en)	2009-04-22	2017-09-12	Resverlogix Corp.	Anti-inflammatory agents
WO2012088266A2 (en)	2010-12-22	2012-06-28	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
JP2014519813A (ja)	2011-04-25	2014-08-21	オーエスアイ・ファーマシューティカルズ，エルエルシー	癌薬剤発見、診断、および治療におけるｅｍｔ遺伝子シグネチャーの使用
RU2640115C2 (ru)	2011-11-01	2017-12-26	Ресверлоджикс Корп.	Фармацевтические композиции замещенных хиназолинонов
WO2013152252A1 (en)	2012-04-06	2013-10-10	OSI Pharmaceuticals, LLC	Combination anti-cancer therapy
LT3495367T (lt)	2012-06-13	2021-02-25	Incyte Holdings Corporation	Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
WO2014026125A1 (en)	2012-08-10	2014-02-13	Incyte Corporation	Pyrazine derivatives as fgfr inhibitors
WO2014080291A2 (en)	2012-11-21	2014-05-30	Rvx Therapeutics Inc.	Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en)	2012-11-21	2015-07-07	Zenith Epigenetics Corp.	Cyclic amines as bromodomain inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
US9271978B2 (en)	2012-12-21	2016-03-01	Zenith Epigenetics Corp.	Heterocyclic compounds as bromodomain inhibitors
LT2986610T (lt) *	2013-04-19	2018-04-10	Incyte Holdings Corporation	Bicikliniai heterociklai, kaip fgfr inhibitoriai
CN103757026B (zh) *	2013-12-20	2017-04-05	广州圣露生物技术有限公司	FGFR2b胞外段的基因序列、多肽及其应用
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SG11201706287PA (en)	2015-02-20	2017-09-28	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
US10111885B2 (en)	2015-03-13	2018-10-30	Resverlogix Corp.	Compositions and therapeutic methods for the treatment of complement-associated diseases
US20190060286A1 (en)	2016-02-29	2019-02-28	University Of Florida Research Foundation, Incorpo	Chemotherapeutic Methods
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
WO2019071144A1 (en)	2017-10-05	2019-04-11	Fulcrum Therapeutics, Inc.	USE OF P38 INHIBITORS TO REDUCE DUX4 EXPRESSION
US10342786B2 (en)	2017-10-05	2019-07-09	Fulcrum Therapeutics, Inc.	P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
ES3061844T3 (en)	2018-05-04	2026-04-07	Incyte Corp	Salts of an fgfr inhibitor
MX2020011718A (es)	2018-05-04	2021-02-15	Incyte Corp	Formas solidas de un inhibidor de receptores del factor de crecimiento de fibroblastos (fgfr) y procesos para prepararlas.
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
US12122767B2 (en)	2019-10-01	2024-10-22	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
TWI891666B (zh)	2019-10-14	2025-08-01	美商英塞特公司	作為ｆｇｆｒ抑制劑之雙環雜環
US11566028B2 (en)	2019-10-16	2023-01-31	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
CA3163875A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2021113462A1 (en)	2019-12-04	2021-06-10	Incyte Corporation	Derivatives of an fgfr inhibitor
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
TW202304459A (zh)	2021-04-12	2023-02-01	美商英塞特公司	包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
JP2024522189A (ja)	2021-06-09	2024-06-11	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての三環式ヘテロ環
EP4352060A1 (en)	2021-06-09	2024-04-17	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1353534A (en)	1971-07-13	1974-05-22	Roche Products Ltd	Pyrimidotriazines and a process for the manufacture thereof
US4025510A (en) *	1975-12-01	1977-05-24	E. I. Du Pont De Nemours And Company	2,4-Diaryl[1,3,4H]thiadiazines fused to quinoxalines
KR100523120B1 (ko) *	1999-10-21	2005-10-20	에프. 호프만-라 로슈 아게	Ｐ38 단백질 키나제 저해제로서 헤테로알킬아미노-치환된이환 질소 헤테로환
BR0113628A (pt) *	2000-08-31	2003-07-01	Hoffmann La Roche	7-oxo-piridopirimidinas como inibidores de uma proliferação celular
US6642381B2 (en) *	2001-12-27	2003-11-04	Hoffman-La Roche Inc.	Pyrimido[5,4-e][1,2,4]triazine-5,7-diamine compounds as protein tyrosine phosphatase inhibitors

2003
- 2003-11-12 PL PL377620A patent/PL377620A1/pl not_active Application Discontinuation
- 2003-11-12 RU RU2005119281/04A patent/RU2340618C2/ru not_active IP Right Cessation
- 2003-11-12 BR BR0316375-0A patent/BR0316375A/pt not_active IP Right Cessation
- 2003-11-12 EP EP03775346A patent/EP1565475B1/en not_active Expired - Lifetime
- 2003-11-12 AT AT03775346T patent/ATE427951T1/de not_active IP Right Cessation
- 2003-11-12 CA CA002506565A patent/CA2506565A1/en not_active Abandoned
- 2003-11-12 DE DE60327097T patent/DE60327097D1/de not_active Expired - Fee Related
- 2003-11-12 KR KR1020057008919A patent/KR20050075028A/ko not_active Ceased
- 2003-11-12 WO PCT/EP2003/012652 patent/WO2004046152A1/en not_active Ceased
- 2003-11-12 AU AU2003283393A patent/AU2003283393A1/en not_active Abandoned
- 2003-11-12 CN CNB2003801035760A patent/CN100357293C/zh not_active Expired - Fee Related
- 2003-11-12 MX MXPA05005028A patent/MXPA05005028A/es active IP Right Grant
- 2003-11-12 JP JP2004552580A patent/JP2006514624A/ja active Pending
- 2003-11-18 US US10/715,666 patent/US6943158B2/en not_active Expired - Fee Related
2005
- 2005-07-27 US US11/190,292 patent/US20050261284A1/en not_active Abandoned

Also Published As

Publication number	Publication date
MXPA05005028A (es)	2005-08-03
CN1714093A (zh)	2005-12-28
EP1565475A1 (en)	2005-08-24
RU2005119281A (ru)	2006-03-20
US6943158B2 (en)	2005-09-13
AU2003283393A1 (en)	2004-06-15
CA2506565A1 (en)	2004-06-03
US20040097493A1 (en)	2004-05-20
EP1565475B1 (en)	2009-04-08
US20050261284A1 (en)	2005-11-24
RU2340618C2 (ru)	2008-12-10
KR20050075028A (ko)	2005-07-19
BR0316375A (pt)	2005-10-04
CN100357293C (zh)	2007-12-26
DE60327097D1 (de)	2009-05-20
ATE427951T1 (de)	2009-04-15
WO2004046152A1 (en)	2004-06-03
JP2006514624A (ja)	2006-05-11

Legal Events

Date	Code	Title	Description
2011-12-30	REFS	Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)

Publication	Publication Date	Title
ATE427951T1 (de)	2009-04-15	Diazinopyrimidine und ihre verwendung als proteinkinaseinhibitoren
AR040787A1 (es)	2005-04-20	6-alcoxi-piridopirimidinas
NZ509939A (en)	2002-08-28	1H-imidazopyridine derivatives useful as TNF or IL-1 inhibitors
IL135537A0 (en)	2001-05-20	Substituted fused heterocyclic compounds
ATE296797T1 (de)	2005-06-15	N-(aryl/heteroaryl/alkylacetyl) amino saüre amide,pharmazeutische zusammensetzungen damit, und methodenzur inhibierung beta-amyloid peptid freisetzung oder synthese
CA2140598A1 (en)	1995-07-28	Prolineamide derivatives
DK0958280T3 (da)	2005-08-29	Arylpiperidinopropanol- og arylpiperazinopropanolderivater og farmaceutiske midler der indeholder disse
TNSN04121A1 (en)	2006-06-01	Acides 3 - (imidazolyl) - 2 - alkoxypropanoiques servant d'inhibiteurs de tafia
MY134226A (en)	2007-11-30	1,2-dihydropyrazol-3-ones which control inflammatory cyctokines
NO940019L (no)	1995-04-20	Fremgangsmåte for fremstilling av svovelholdige imidazolderivater
EP0889034A4 (en)	2001-06-06	AMINOPYRIDINE DERIVATIVES
SE8602449D0 (sv)	1986-05-29	11-beta substituted steroids and process for their preparation
PL341013A1 (en)	2001-03-12	Acylated heteroalicyclic derivatives
EP2527352A3 (en)	2013-07-10	Caprazene derivatives
PL324197A1 (en)	1998-05-11	Derivatives of hydroxylamine and pharmaceutic agents against ischaemia
NZ337142A (en)	2000-10-27	Hydroxamic acid compounds
DE68910090D1 (de)	1993-11-25	Verwendung heterozyklischer Amide zur Verhinderung der Tumormetastasierung.
AU7296300A (en)	2001-04-10	Preparing amidines derived from 6-hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid